Halozyme Therapeutics, Inc. (HALO)
69.63
+0.64
(+0.93%)
USD |
NASDAQ |
Jun 23, 10:05
Halozyme Therapeutics Accounts Receivable (Quarterly) : 457.99M for March 31, 2026
Accounts Receivable (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Accounts Receivable (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 457.99M |
| December 31, 2025 | 441.27M |
| September 30, 2025 | 346.04M |
| June 30, 2025 | 316.34M |
| March 31, 2025 | 304.62M |
| December 31, 2024 | 308.46M |
| September 30, 2024 | 285.74M |
| June 30, 2024 | 214.52M |
| March 31, 2024 | 195.90M |
| December 31, 2023 | 234.21M |
| September 30, 2023 | 217.32M |
| June 30, 2023 | 246.18M |
| March 31, 2023 | 194.88M |
| December 31, 2022 | 231.07M |
| September 30, 2022 | 233.30M |
| June 30, 2022 | 189.37M |
| March 31, 2022 | 113.76M |
| December 31, 2021 | 90.98M |
| September 30, 2021 | 112.10M |
| June 30, 2021 | 153.20M |
| March 31, 2021 | 88.39M |
| December 31, 2020 | 97.73M |
| September 30, 2020 | 62.55M |
| June 30, 2020 | 37.40M |
| March 31, 2020 | 29.75M |
| Date | Value |
|---|---|
| December 31, 2019 | 59.44M |
| September 30, 2019 | 40.74M |
| June 30, 2019 | 32.22M |
| March 31, 2019 | 28.16M |
| December 31, 2018 | 30.00M |
| September 30, 2018 | 27.66M |
| June 30, 2018 | 33.58M |
| March 31, 2018 | 26.57M |
| December 31, 2017 | 22.13M |
| September 30, 2017 | 14.70M |
| June 30, 2017 | 14.47M |
| March 31, 2017 | 12.45M |
| December 31, 2016 | 15.68M |
| September 30, 2016 | 17.68M |
| June 30, 2016 | 23.23M |
| March 31, 2016 | 25.54M |
| December 31, 2015 | 32.41M |
| September 30, 2015 | 8.392M |
| June 30, 2015 | 9.738M |
| March 31, 2015 | 7.725M |
| December 31, 2014 | 9.149M |
| September 30, 2014 | 8.275M |
| June 30, 2014 | 12.90M |
| March 31, 2014 | 10.96M |
| December 31, 2013 | 9.097M |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Accounts Receivable (Quarterly) Benchmarks
| Vertex Pharmaceuticals, Inc. | 1.996B |
| Agenus, Inc. | 46.56M |
| Altimmune, Inc. | 1.665M |
| Lineage Cell Therapeutics, Inc. | 1.391M |
| Amgen, Inc. | 9.138B |